Literature DB >> 9863061

Overexpression of human DNA topoisomerase II alpha by fusion to enhanced green fluorescent protein.

Y Y Mo1, K A Ameiss, W T Beck.   

Abstract

DNA topoisomerase (topo) II alpha is a major target for many anticancer agents. However, progress towards understanding how these agents interact with this enzyme in human cells and how resistance to these agents arises is greatly impeded by difficulties in expressing this gene. Here, we report on achieving a high level of expression of a full-length human topo II alpha gene in human cells. We started with the topo II alpha cDNA driven by a strong cytomegalovirus promoter and transiently transfected HeLa cells. Although topo II alpha mRNA was consistently detected in transfected cells, no exogenous topo II alpha protein was detected. By contrast, when the same cDNA was fused to an enhanced green fluorescent protein (EGFP), we detected a high level of expression at both mRNA and protein levels. The exogenous topo II alpha was localized to cell nuclei as expected, indicating that the fusion protein is properly folded. Furthermore, overexpression of the EGFP-topo II alpha fusion protein increased the sensitivity of the transfected cells to teniposide, suggesting that it functions as the endogenous counterpart. Thus, in addition to being used as a gene tag, the GFP fusion approach may be generally applicable for expressing genes, such as topo II alpha, that are difficult to express by conventional methods.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9863061     DOI: 10.2144/98256cr04

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  10 in total

1.  Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.

Authors:  D W Stacey; M Hitomi; G Chen
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Protein kinase C delta activates topoisomerase IIalpha to induce apoptotic cell death in response to DNA damage.

Authors:  Kiyotsugu Yoshida; Tomoko Yamaguchi; Hirokuni Shinagawa; Naoe Taira; Keiichi I Nakayama; Yoshio Miki
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

Review 3.  DNA topoisomerase II and its growing repertoire of biological functions.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

Review 4.  Assays for mitotic chromosome condensation in live yeast and mammalian cells.

Authors:  Gabriel Neurohr; Daniel W Gerlich
Journal:  Chromosome Res       Date:  2009       Impact factor: 5.239

Review 5.  Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?

Authors:  Atocha Romero; Trinidad Caldés; Eduardo Díaz-Rubio; Miguel Martín
Journal:  Clin Transl Oncol       Date:  2012-03       Impact factor: 3.405

6.  The dynamics of DNA topoisomerase IIalpha in living cells.

Authors:  John R Daum; Yin Yuan Mo; Gary J Gorbsky
Journal:  Methods Mol Biol       Date:  2009

7.  Rapid exchange of mammalian topoisomerase II alpha at kinetochores and chromosome arms in mitosis.

Authors:  Penny A Tavormina; Marie-George Côme; Joanna R Hudson; Yin-Yuan Mo; William T Beck; Gary J Gorbsky
Journal:  J Cell Biol       Date:  2002-07-08       Impact factor: 10.539

8.  A novel chromatin tether domain controls topoisomerase IIα dynamics and mitotic chromosome formation.

Authors:  Andrew B Lane; Juan F Giménez-Abián; Duncan J Clarke
Journal:  J Cell Biol       Date:  2013-11-11       Impact factor: 10.539

9.  Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer.

Authors:  Tommaso Susini; Barbara Berti; Carlo Carriero; Ketty Tavella; Jacopo Nori; Ermanno Vanzi; Cecilia Molino; Mariarosaria Di Tommaso; Marco Santini; Valeria Saladino; Simonetta Bianchi
Journal:  Onco Targets Ther       Date:  2014-11-17       Impact factor: 4.147

10.  TOPBP1 recruits TOP2A to ultra-fine anaphase bridges to aid in their resolution.

Authors:  Ronan Broderick; Jadwiga Nieminuszczy; Andrew N Blackford; Alicja Winczura; Wojciech Niedzwiedz
Journal:  Nat Commun       Date:  2015-03-12       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.